Does Gilead’s 2025 Rally Match Its Cash Flow Outlook and Oncology Pipeline Prospects
- If you are wondering whether Gilead Sciences is still a smart buy after its big run up, or if the value has already been priced in, you are in the right place to unpack what the market might be missing.
- Gilead has quietly pushed its share price to about $125.67, with returns of 3.6% over the last week, 0.3% over the past month, and a much stronger 36.8% year to date and 37.5% over the last year, building on a 65.1% three year and 168.8% five year climb.
- Recent headlines around Gilead have focused on its expanding oncology pipeline and ongoing work in HIV and antiviral treatments. Together these have reinforced the narrative that this is a mature company still finding new growth levers. At the same time, regulatory and competitive developments in the biotech space have sharpened investor focus on how durable Gilead's cash flows really are.
- On our framework, Gilead scores a solid 5 out of 6 on valuation checks, suggesting it screens as undervalued on most metrics. From here we will walk through the main valuation approaches we use, before finishing with a more holistic way to think about what this stock is truly worth.
Approach 1: Gilead Sciences Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model estimates what a company is worth today by projecting the cash it can generate in the future and discounting those cash flows back to the present.
For Gilead Sciences, the latest twelve month Free Cash Flow is about $9.1 billion. Analysts and extrapolations used in this 2 Stage Free Cash Flow to Equity model project Free Cash Flow rising to around $14.3 billion by 2029, with further growth taking it to roughly $17.7 billion by 2035. Simply Wall St uses detailed forecasts for the next few years and then extends the trend with gradually moderating growth assumptions.
When these future cash flows are discounted back to today, the model produces an intrinsic value of roughly $262.88 per share. Compared with the current share price near $125, the DCF implies the stock is about 52.2% undervalued, which indicates that the market may be heavily discounting Gilead's future cash generation.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Gilead Sciences is undervalued by 52.2%. Track this in your watchlist or portfolio, or discover 904 more undervalued stocks based on cash flows.
Approach 2: Gilead Sciences Price vs Earnings
For profitable, established companies like Gilead Sciences, the price to earnings, or PE, ratio is a useful way to see what investors are willing to pay today for each dollar of current earnings. A higher PE often reflects stronger growth expectations or lower perceived risk, while a lower PE tends to signal slower growth or higher uncertainty, so what counts as a fair PE depends on both outlook and risk profile.
Gilead currently trades on a PE of about 19.23x, which is slightly below the broader Biotechs industry average of roughly 21.58x and well below the peer group average of around 62.06x. Simply Wall St also calculates a proprietary Fair Ratio of 28.35x, which represents the PE that might be expected given Gilead's specific mix of earnings growth, margins, industry position, size and risk characteristics. This Fair Ratio is intended to be more informative than a simple comparison with peers or the sector because it adjusts for the fact that not all biotechs have the same quality, scale, or risk profile.
With the market pricing Gilead at 19.23x versus a Fair Ratio of 28.35x, the shares appear to be trading at a lower multiple than this reference point.
Result: UNDERVALUED
PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1459 companies where insiders are betting big on explosive growth.
Upgrade Your Decision Making: Choose your Gilead Sciences Narrative
Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story about a company connected directly to your assumptions for future revenue, earnings, margins, and fair value.
On Simply Wall St, Narratives live in the Community page and turn your view of a business into a dynamic forecast and valuation, so you can clearly see whether your Fair Value suggests you should be buying, holding, or selling at the current price.
Because Narratives update automatically when new information like earnings results, drug trial news, or policy changes comes in, they give you a living framework instead of a static snapshot, helping you quickly tell whether the investment case is getting stronger or weaker.
For example, one Gilead Sciences Narrative might lean toward a higher fair value near 153 dollars based on assumptions about long term HIV growth and oncology upside, while another more cautious Narrative could anchor closer to about 91 to 98 dollars. The gap between those views makes it easier to see which story, and which assumptions, you actually agree with before you act.
Do you think there's more to the story for Gilead Sciences? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com